Incyte Corporation

NASDAQ:INCY

Biotechnology

Healthcare
$117.80 -0.78%

-$0.77 today

Market cap
$24.01B
Beta
0.79
P/E (TTM)
13.7
EPS (TTM)
$7.18
52W Low $66.74High $112.29

Volume 1.21M

Average 1.58M

INCY Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Incyte CorporationNASDAQ: INCY

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows in line with its trailing trend

Q2 FY2026 weighted avg shares of 200.38M shares rose 3.3% year over year, ahead of the +2.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at -4.2% a year.

Context

  • Weighted avg shares increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3.3% holds above the trailing-twelve-month pace of +2.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
200.38M+0.5% QoQ
Last fiscal yearDec 2025
195.2M-5.7% YoY
LTMJun 2026
198.21M+2.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.3%——
1 year-5.7%——
3-year CAGR-4.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
195.2M USD
Year-over-year change
-5.7%
4-year CAGR
-3.0%

Weighted Avg Shares vs competitors

How INCY compares with its peers on the latest reported figures

  • INCY's LTM Jun 2026 weighted avg shares of 198.21M shares is the 3rd highest of the 11 companies compared; the peer median is 105.22M shares.
  • Its year-over-year change of +2.5% is the 6th highest of 10, against a peer median of +4.1%.
  • Over three fiscal years its annual growth of -4.2% compares with a peer median of +4.9%.
INCY Competitors Peer median
Weighted Avg Shares for INCY and competitors
Company Period LTM YoY 3-year CAGR
GMABGenmab A/SLTM Jun 2026614.84M —-1.7%
EXELExelixis, Inc.LTM Jul 2026262.28M -6.5%-5.5%
INCYIncyte CorporationLTM Jun 2026198.21M +2.5%-4.2%
LEGNLegend Biotech CorporationLTM Sep 2026185.87M +1.7%+5.0%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026179.3M +96.8%+77.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026106.95M +29.6%+21.3%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026103.48M -3.2%-0.8%
VSTMVerastem, Inc.LTM Mar 202680.25M +101.5%+62.5%
CGEMCullinan Therapeutics, Inc.LTM Mar 202659.11M +2.4%+9.3%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 202619.76M +4.1%+4.7%
Peer median (excluding INCY) 105.22M+4.1%+4.9%

Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.99B3.39B3.7B4.24B5.14B
Cost of Revenue150.99M207M254.99M312.1M372.1M
Gross Profit2.84B3.19B3.44B3.93B4.77B
Gross Margin94.9%93.9%93.1%92.6%92.8%
Research & Development1.46B1.59B1.63B2.61B2.05B
Selling, General & Admin739.56M1B1.16B1.22B1.38B
Operating Expenses2.25B2.6B2.79B3.83B3.43B
Depreciation & Amortization57.84M67.86M82.66M89.25M93.29M
EBITDA630.2M599.64M919.43M408.16M1.76B
EBITDA Margin21.1%17.7%24.9%9.6%34.2%
Operating Income585.78M591.63M655.36M101.29M1.34B
Operating Margin19.6%17.4%17.7%2.4%26.1%
Interest Income000128.71M105.6M
Interest Expense1.91M2.67M2.55M2.28M2.43M
Other Income / Expenses(15.33M)(62.51M)178.86M215.34M321.66M
Income Before Tax570.44M529.12M834.22M316.63M1.66B
Pre-Tax Margin19.1%15.6%22.6%7.5%32.4%
Income Tax Expense(378.14M)188.46M236.62M284.02M377.8M
Net Income948.58M340.66M597.6M32.62M1.29B
Net Margin31.8%10.0%16.2%0.8%25.0%
EPS (Basic)4.301.532.670.166.59
EPS (Diluted)4.271.522.650.156.41
Weighted Avg Shares220.43M222M223.63M207.11M195.2M
Weighted Avg Shares (Diluted)222.07M223.96M225.93M210.53M200.7M

Incyte Corporation

NASDAQ:INCY

Intrinsic Alpha fair value

Locked

Current Price

$117.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.